Breaking News Instant updates and real-time market news.

MDWD

MediWound

$1.79 /

-0.03 (-1.65%)

07:04
07/07/22
07/07
07:04
07/07/22
07:04

MediWound's EscharEx shows positive Phase 2 results in leg ulcers

MediWound announced positive results from its U.S. prospective, open-label, single-arm, Phase 2 pharmacology clinical study of EscharEx for the debridement of lower leg ulcers. The study was designed to evaluate the clinical performance, safety and pharmacology effect of EscharEx in debridement of venous leg ulcers - VLUs - and diabetic foot ulcers - DFUs -. 70% of patients achieved complete debridement during the course of treatment within up to 8 applications. On average, complete debridement was achieved after 3.9 applications of EscharEx. Additionally, an average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period. Biomarker analysis from wound fluid is on-going and safety data shows that EscharEx is safe and well-tolerated. The study evaluated the clinical performance, safety, and pharmacology effect of EscharEx in the debridement of lower leg ulcers. The study evaluated the safety and efficacy of debridement as measured by incidence of, and time to complete debridement.

  • 19

    Jul

  • 03

    Mar

OTHER BREAKING NEWS FROM THE FLY

Recommendations
PowerSchool price target raised to $19 from $18 at Barclays » 05:52
08/09/22
08/09
05:52
08/09/22
05:52
PWSC

PowerSchool

$15.48 /

-0.07 (-0.45%)

Barclays analyst Saket…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PWSC PowerSchool
$15.48 /

-0.07 (-0.45%)

PWSC PowerSchool
$15.48 /

-0.07 (-0.45%)

07/18/22 Piper Sandler
PowerSchool price target lowered to $15 from $17 at Piper Sandler
07/13/22 Goldman Sachs
PowerSchool upgraded to Neutral from Sell at Goldman Sachs
07/12/22 Barclays
PowerSchool price target lowered to $18 from $20 at Barclays
03/30/22 Cantor Fitzgerald
PowerSchool initiated with an Overweight at Cantor Fitzgerald
PWSC PowerSchool
$15.48 /

-0.07 (-0.45%)

Recommendations
Palo Alto Networks price target lowered to $605 from $645 at Barclays » 05:51
08/09/22
08/09
05:51
08/09/22
05:51
PANW

Palo Alto Networks

$500.88 /

-0.11 (-0.02%)

Barclays analyst Saket…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PANW Palo Alto Networks
$500.88 /

-0.11 (-0.02%)

PANW Palo Alto Networks
$500.88 /

-0.11 (-0.02%)

08/01/22 Wolfe Research
Palo Alto Networks initiated with an Outperform at Wolfe Research
07/22/22 Citi
Palo Alto Networks price target lowered to $605 from $610 at Citi
07/13/22 Piper Sandler
Palo Alto Networks price target lowered to $650 from $675 at Piper Sandler
07/08/22 BMO Capital
Palo Alto Networks price target raised to $650 from $615 at BMO Capital
PANW Palo Alto Networks
$500.88 /

-0.11 (-0.02%)

PANW Palo Alto Networks
$500.88 /

-0.11 (-0.02%)

PANW Palo Alto Networks
$500.88 /

-0.11 (-0.02%)

PANW Palo Alto Networks
$500.88 /

-0.11 (-0.02%)

Recommendations
GoodRx price target raised to $13 from $12 at Barclays » 05:50
08/09/22
08/09
05:50
08/09/22
05:50
GDRX

GoodRx

$7.78 /

+0.715 (+10.12%)

Barclays analyst Steve…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GDRX GoodRx
$7.78 /

+0.715 (+10.12%)

GDRX GoodRx
$7.78 /

+0.715 (+10.12%)

07/20/22 Barclays
GoodRx price target lowered to $12 from $15 at Barclays
07/18/22 Guggenheim
GoodRx price target lowered to $13 from $17 at Guggenheim
06/22/22 Baird
GoodRx price target lowered to $6 from $7 at Baird
06/13/22 Cowen
GoodRx price target lowered to $9 from $22 at Cowen
GDRX GoodRx
$7.78 /

+0.715 (+10.12%)

GDRX GoodRx
$7.78 /

+0.715 (+10.12%)

GDRX GoodRx
$7.78 /

+0.715 (+10.12%)

Recommendations
Americold Realty Trust price target lowered to $28 from $29 at Barclays » 05:49
08/09/22
08/09
05:49
08/09/22
05:49
COLD

Americold Realty Trust

$31.18 /

+0.13 (+0.42%)

Barclays analyst Anthony…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
COLD Americold Realty Trust
$31.18 /

+0.13 (+0.42%)

COLD Americold Realty Trust
$31.18 /

+0.13 (+0.42%)

08/08/22 RBC Capital
Americold Realty downgraded to Sector Perform from Outperform at RBC Capital
07/07/22 Baird
Americold Realty Trust price target raised to $33 from $29 at Baird
06/14/22 Barclays
Americold Realty Trust price target raised to $29 from $27 at Barclays
06/02/22 BofA
Americold Realty Trust upgraded to Neutral from Underperform at BofA
COLD Americold Realty Trust
$31.18 /

+0.13 (+0.42%)

COLD Americold Realty Trust
$31.18 /

+0.13 (+0.42%)

Recommendations
Trex Company price target lowered to $53 from $63 at Barclays » 05:49
08/09/22
08/09
05:49
08/09/22
05:49
TREX

Trex Company

$63.74 /

-0.91 (-1.41%)

Barclays analyst Matthew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TREX Trex Company
$63.74 /

-0.91 (-1.41%)

TREX Trex Company
$63.74 /

-0.91 (-1.41%)

07/15/22 JPMorgan
Trex Company price target lowered to $54 from $66 at JPMorgan
07/14/22 Barclays
Trex Company price target lowered to $63 from $68 at Barclays
06/08/22 JPMorgan
Azek valuation remains attractive versus Trex, says JPMorgan
06/03/22 Barclays
Barclays continues to prefer Azek shares over Trex
TREX Trex Company
$63.74 /

-0.91 (-1.41%)

TREX Trex Company
$63.74 /

-0.91 (-1.41%)

Recommendations
Oportun Financial price target lowered to $12 from $15 at Barclays » 05:48
08/09/22
08/09
05:48
08/09/22
05:48
OPRT

Oportun Financial

$10.77 /

+0.705 (+7.01%)

Barclays analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OPRT Oportun Financial
$10.77 /

+0.705 (+7.01%)

OPRT Oportun Financial
$10.77 /

+0.705 (+7.01%)

07/11/22 Keefe Bruyette
Oportun Financial price target lowered to $14 from $21 at Keefe Bruyette
07/11/22 Barclays
Oportun Financial price target lowered to $15 from $27 at Barclays
06/06/22 Loop Capital
Oportun Financial in unique position for big upside, says Loop Capital
03/14/22 Loop Capital
Oportun Financial initiated with a Buy at Loop Capital
OPRT Oportun Financial
$10.77 /

+0.705 (+7.01%)

Recommendations
MacroGenics price target lowered to $8 from $18 at Barclays » 05:47
08/09/22
08/09
05:47
08/09/22
05:47
MGNX

MacroGenics

$4.52 /

+0.135 (+3.08%)

Barclays analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MGNX MacroGenics
$4.52 /

+0.135 (+3.08%)

MGNX MacroGenics
$4.52 /

+0.135 (+3.08%)

07/11/22 BTIG
MacroGenics price target lowered to $6 at BTIG
07/11/22 BMO Capital
MacroGenics downgraded to Market Perform from Outperform at BMO Capital
05/05/22 Guggenheim
MacroGenics downgraded to Neutral yesterday at Guggenheim
05/04/22 Guggenheim
MacroGenics downgraded to Neutral from Buy at Guggenheim
MGNX MacroGenics
$4.52 /

+0.135 (+3.08%)

Downgrade
Professional Holding downgraded to Market Perform on buyout at Raymond James » 05:46
08/09/22
08/09
05:46
08/09/22
05:46
PFHD

Professional Holding

$29.65 /

+6.58 (+28.52%)

, SBCF

Seacoast Banking

$34.58 /

-2.16 (-5.88%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFHD Professional Holding
$29.65 /

+6.58 (+28.52%)

SBCF Seacoast Banking
$34.58 /

-2.16 (-5.88%)

PFHD Professional Holding
$29.65 /

+6.58 (+28.52%)

05:04 Today Raymond James
Professional Holding downgraded to Market Perform at Raymond James
05/09/22 Piper Sandler
Professional Holding downgraded to Neutral from Overweight at Piper Sandler
SBCF Seacoast Banking
$34.58 /

-2.16 (-5.88%)

07/11/22 B. Riley
Seacoast Banking price target lowered to $34 from $36 at B. Riley
07/06/22 Truist
Seacoast Banking price target lowered to $39 from $42 at Truist
01/17/22 Keefe Bruyette
Seacoast Banking initiated with a Market Perform at Keefe Bruyette
10/06/21 B. Riley
Seacoast Banking downgraded to Neutral from Buy at B. Riley
PFHD Professional Holding
$29.65 /

+6.58 (+28.52%)

SBCF Seacoast Banking
$34.58 /

-2.16 (-5.88%)

Periodicals
Samsung plans $3.3B investment in Vietnam, South China Morning Post reports » 05:45
08/09/22
08/09
05:45
08/09/22
05:45
SSNLF

Samsung

$57.75 /

+ (+0.00%)

Samsung plans to make an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SSNLF Samsung
$57.75 /

+ (+0.00%)

SSNLF Samsung
$57.75 /

+ (+0.00%)

06/22/22 Loop Capital
Samsung initiated with a Buy at Loop Capital
06/13/22 KeyBanc
Qualcomm price target raised to $220 from $200 at KeyBanc
06/13/22 UBS
Micron price target lowered to $115 from $120 at UBS
06/01/22 Craig-Hallum
Ambarella price target lowered to $100 from $170 at Craig-Hallum
SSNLF Samsung
$57.75 /

+ (+0.00%)

SSNLF Samsung
$57.75 /

+ (+0.00%)

SSNLF Samsung
$57.75 /

+ (+0.00%)

Recommendations
Bandwidth price target lowered to $19 from $20 at Citi » 05:44
08/09/22
08/09
05:44
08/09/22
05:44
BAND

Bandwidth

$16.95 /

+0.915 (+5.71%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BAND Bandwidth
$16.95 /

+0.915 (+5.71%)

BAND Bandwidth
$16.95 /

+0.915 (+5.71%)

08/04/22 Canaccord
Bandwidth price target lowered to $50 from $71 at Canaccord
08/04/22 JMP Securities
Bandwidth price target lowered to $55 from $100 at JMP Securities
07/26/22 Barclays
Bandwidth price target lowered to $30 from $45 at Barclays
07/13/22 Piper Sandler
Bandwidth price target lowered to $29 from $40 at Piper Sandler
BAND Bandwidth
$16.95 /

+0.915 (+5.71%)

BAND Bandwidth
$16.95 /

+0.915 (+5.71%)

Periodicals
Amazon's iRobot, One Medical deals show hunt for fourth 'pillar,' Bloomberg says » 05:44
08/09/22
08/09
05:44
08/09/22
05:44
AMZN

Amazon.com

$139.42 /

-1.37 (-0.97%)

, IRBT

iRobot

$59.58 /

+0.07 (+0.12%)

, ONEM

1Life Healthcare

$16.85 /

-0.12 (-0.71%)

Amazon's (AMZN)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$139.42 /

-1.37 (-0.97%)

IRBT iRobot
$59.58 /

+0.07 (+0.12%)

ONEM 1Life Healthcare
$16.85 /

-0.12 (-0.71%)

AMZN Amazon.com
$139.42 /

-1.37 (-0.97%)

08/08/22 B. Riley
B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
08/05/22 DA Davidson
Amazon may be be more willing to do M&A under Jassy, says DA Davidson
07/29/22 UBS
Amazon.com price target raised to $180 from $167 at UBS
07/29/22 BofA
Amazon price target bumped to $170 at BofA after 'mostly positive' quarter
IRBT iRobot
$59.58 /

+0.07 (+0.12%)

08/08/22 Northland
iRobot downgraded to Market Perform from Outperform at Northland
08/05/22 DA Davidson
Amazon may be be more willing to do M&A under Jassy, says DA Davidson
07/14/22 Citi
Citi cuts iRobot target, opens 'negative 30-day catalyst watch'
05/06/22 JPMorgan
iRobot downgraded to Underweight on risks to guidance at JPMorgan
ONEM 1Life Healthcare
$16.85 /

-0.12 (-0.71%)

08/05/22 DA Davidson
Amazon may be be more willing to do M&A under Jassy, says DA Davidson
07/27/22 Stifel
Oak Street Health price target raised to $35 from $25 at Stifel
07/27/22 Stifel
1Life Healthcare downgraded to Hold from Buy at Stifel
07/25/22 Truist
1Life Healthcare downgraded to Hold from Buy at Truist
AMZN Amazon.com
$139.42 /

-1.37 (-0.97%)

IRBT iRobot
$59.58 /

+0.07 (+0.12%)

ONEM 1Life Healthcare
$16.85 /

-0.12 (-0.71%)

AMZN Amazon.com
$139.42 /

-1.37 (-0.97%)

ONEM 1Life Healthcare
$16.85 /

-0.12 (-0.71%)

AMZN Amazon.com
$139.42 /

-1.37 (-0.97%)

IRBT iRobot
$59.58 /

+0.07 (+0.12%)

ONEM 1Life Healthcare
$16.85 /

-0.12 (-0.71%)

AMZN Amazon.com
$139.42 /

-1.37 (-0.97%)

IRBT iRobot
$59.58 /

+0.07 (+0.12%)

ONEM 1Life Healthcare
$16.85 /

-0.12 (-0.71%)

Recommendations
MediaAlpha price target lowered to $12 from $15 at Citi » 05:44
08/09/22
08/09
05:44
08/09/22
05:44
MAX

MediaAlpha

$9.37 /

-0.54 (-5.45%)

Citi analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MAX MediaAlpha
$9.37 /

-0.54 (-5.45%)

MAX MediaAlpha
$9.37 /

-0.54 (-5.45%)

05/13/22 RBC Capital
MediaAlpha price target lowered to $13 from $18 at RBC Capital
03/10/22 RBC Capital
MediaAlpha price target lowered to $18 from $24 at RBC Capital
02/25/22 Canaccord
MediaAlpha price target lowered to $20 from $30 at Canaccord
02/23/22 Citi
MediaAlpha downgraded to Neutral from Buy at Citi
MAX MediaAlpha
$9.37 /

-0.54 (-5.45%)

Recommendations
Valvoline price target lowered to $35 from $37 at Citi » 05:42
08/09/22
08/09
05:42
08/09/22
05:42
VVV

Valvoline

$28.86 /

+0.175 (+0.61%)

Citi analyst Chasen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VVV Valvoline
$28.86 /

+0.175 (+0.61%)

VVV Valvoline
$28.86 /

+0.175 (+0.61%)

08/03/22 Citi
Valvoline price target raised to $37 from $35 at Citi
06/16/22 Jefferies
Valvoline price target lowered to $40 from $44 at Jefferies
05/26/22 Jefferies
Deal for all of Valvoline doesn't appear to be Aramco focus, says Jefferies
05/12/22 JPMorgan
Valvoline upgraded to Overweight on valuation at JPMorgan
VVV Valvoline
$28.86 /

+0.175 (+0.61%)

VVV Valvoline
$28.86 /

+0.175 (+0.61%)

VVV Valvoline
$28.86 /

+0.175 (+0.61%)

Recommendations
GrafTech price target lowered to $7.50 from $10 at Citi » 05:40
08/09/22
08/09
05:40
08/09/22
05:40
EAF

GrafTech

$6.67 /

-0.29 (-4.17%)

Citi analyst Alexander…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EAF GrafTech
$6.67 /

-0.29 (-4.17%)

EAF GrafTech
$6.67 /

-0.29 (-4.17%)

07/13/22 RBC Capital
RBC Capital cuts GrafTech to Sector Perform amid reduced long-term pricing terms
07/13/22 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
06/07/22 Citi
GrafTech downgraded to Neutral at Citi on lack of near-term catalysts
06/07/22 Citi
GrafTech downgraded to Neutral from Buy at Citi
EAF GrafTech
$6.67 /

-0.29 (-4.17%)

EAF GrafTech
$6.67 /

-0.29 (-4.17%)

Recommendations
Acadia Pharmaceuticals price target raised to $17 from $15 at Citi » 05:40
08/09/22
08/09
05:40
08/09/22
05:40
ACAD

Acadia Pharmaceuticals

$16.65 /

+0.225 (+1.37%)

Citi analyst Neena…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ACAD Acadia Pharmaceuticals
$16.65 /

+0.225 (+1.37%)

ACAD Acadia Pharmaceuticals
$16.65 /

+0.225 (+1.37%)

08/08/22 Cowen
Acadia Pharmaceuticals price target lowered to $21 from $32 at Cowen
08/05/22 Citi
Acadia Pharmaceuticals downgraded to Neutral from Buy at Citi
06/22/22 Canaccord
Acadia Pharmaceuticals price target lowered to $20 from $31 at Canaccord
06/22/22 Citi
Acadia Pharmaceuticals price target lowered to $19 from $32 at Citi
ACAD Acadia Pharmaceuticals
$16.65 /

+0.225 (+1.37%)

ACAD Acadia Pharmaceuticals
$16.65 /

+0.225 (+1.37%)

ACAD Acadia Pharmaceuticals
$16.65 /

+0.225 (+1.37%)

Recommendations
Clover Health price target raised to $3.50 from $3 at Citi » 05:39
08/09/22
08/09
05:39
08/09/22
05:39
CLOV

Clover Health

$3.40 /

+0.14 (+4.30%)

Citi analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CLOV Clover Health
$3.40 /

+0.14 (+4.30%)

CLOV Clover Health
$3.40 /

+0.14 (+4.30%)

02/24/22 Canaccord
Clover Health price target raised to $7 from $6 at Canaccord
02/17/22 Citi
Citi opens 'negative catalyst watches' in health care services
02/02/22 Cowen
Clover Health upgraded to Market Perform from Underperform at Cowen
01/19/22 SVB Leerink
Clover Health initiated with a Market Perform at SVB Leerink
CLOV Clover Health
$3.40 /

+0.14 (+4.30%)

  • 18
    Nov
CLOV Clover Health
$3.40 /

+0.14 (+4.30%)

CLOV Clover Health
$3.40 /

+0.14 (+4.30%)

Recommendations
Palantir price target lowered to $6 from $7 at Citi » 05:38
08/09/22
08/09
05:38
08/09/22
05:38
PLTR

Palantir

$9.82 /

-1.625 (-14.20%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PLTR Palantir
$9.82 /

-1.625 (-14.20%)

PLTR Palantir
$9.82 /

-1.625 (-14.20%)

05:18 Today Deutsche Bank
Palantir downgraded to Sell from Hold at Deutsche Bank
08/08/22 Jefferies
Palantir price target lowered to $12 from $13 at Jefferies
08/03/22 RBC Capital
U.S. federal spending tracker 'worrisome' for Palantir, says RBC Capital
07/22/22 Monness Crespi
Monness downgrades Palantir, says recent rally may be unsustainable
PLTR Palantir
$9.82 /

-1.625 (-14.20%)

PLTR Palantir
$9.82 /

-1.625 (-14.20%)

PLTR Palantir
$9.82 /

-1.625 (-14.20%)

PLTR Palantir
$9.82 /

-1.625 (-14.20%)

Recommendations
RBC Bearings price target raised to $250 from $200 at Citi » 05:37
08/09/22
08/09
05:37
08/09/22
05:37
ROLL

RBC Bearings

$243.51 /

+3.22 (+1.34%)

Citi analyst Timothy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ROLL RBC Bearings
$243.51 /

+3.22 (+1.34%)

07/19/22 Truist
RBC Bearings price target lowered to $235 from $250 at Truist
06/23/22 BofA
RBC Bearings downgraded to Neutral on valuation at BofA
06/23/22 BofA
RBC Bearings downgraded to Neutral from Buy at BofA
03/11/22 Wells Fargo
RBC Bearings initiated with an Overweight at Wells Fargo
ROLL RBC Bearings
$243.51 /

+3.22 (+1.34%)

  • 22
    Sep
Recommendations
TaskUs price target lowered to $23 from $28 at Citi » 05:36
08/09/22
08/09
05:36
08/09/22
05:36
TASK

TaskUs

$23.49 /

+0.565 (+2.47%)

Citi analyst Ryan Potter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TASK TaskUs
$23.49 /

+0.565 (+2.47%)

TASK TaskUs
$23.49 /

+0.565 (+2.47%)

07/20/22 JPMorgan
TaskUs price target lowered to $35 from $41 at JPMorgan
07/19/22 Citi
TaskUs initiated with a Buy at Citi
06/30/22 Morgan Stanley
TaskUs price target lowered to $28 from $35 at Morgan Stanley
05/10/22 BTIG
TaskUs price target lowered to $45 from $60 at BTIG
TASK TaskUs
$23.49 /

+0.565 (+2.47%)

  • 21
    Oct
TASK TaskUs
$23.49 /

+0.565 (+2.47%)

Recommendations
eHealth price target lowered to $9 from $13 at Citi » 05:35
08/09/22
08/09
05:35
08/09/22
05:35
EHTH

eHealth

$8.29 /

+0.52 (+6.69%)

Citi analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EHTH eHealth
$8.29 /

+0.52 (+6.69%)

EHTH eHealth
$8.29 /

+0.52 (+6.69%)

05/05/22 Deutsche Bank
eHealth price target lowered to $10 from $19 at Deutsche Bank
03/31/22 Credit Suisse
eHealth assumed with a Neutral at Credit Suisse
03/21/22 Citi
eHealth downgraded to Neutral from Buy at Citi
03/03/22 Credit Suisse
eHealth price target lowered to $16 from $31 at Credit Suisse
EHTH eHealth
$8.29 /

+0.52 (+6.69%)

EHTH eHealth
$8.29 /

+0.52 (+6.69%)

Downgrade
Crispr Therapeutics downgraded to Equal Weight from Overweight at Barclays » 05:33
08/09/22
08/09
05:33
08/09/22
05:33
CRSP

Crispr Therapeutics

$81.33 /

-0.02 (-0.02%)

Barclays analyst Gena…

Barclays analyst Gena Wang downgraded Crispr Therapeutics to Equal Weight from Overweight with a price target of $88, down from $99. The company's Q2 release was "largely incremental," highlighting the progress of its multiple clinical programs, Wang tells investors in a research note. The analyst is stepping to the sidelines "given some questions on durability" of the allogeneic CAR-T programs and lack of other major data catalysts in the next 12 months.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$81.33 /

-0.02 (-0.02%)

CRSP Crispr Therapeutics
$81.33 /

-0.02 (-0.02%)

08/08/22 Chardan
Crispr Therapeutics price target lowered to $154 from $164 at Chardan
08/02/22 Citi
Crispr Therapeutics price target raised to $83 from $53 at Citi
06/23/22 Oppenheimer
Crispr Therapeutics price target lowered to $122 from $150 at Oppenheimer
06/23/22 Evercore ISI
Crispr Therapeutics downgraded to In Line from Outperform at Evercore ISI
CRSP Crispr Therapeutics
$81.33 /

-0.02 (-0.02%)

CRSP Crispr Therapeutics
$81.33 /

-0.02 (-0.02%)

CRSP Crispr Therapeutics
$81.33 /

-0.02 (-0.02%)

CRSP Crispr Therapeutics
$81.33 /

-0.02 (-0.02%)

Downgrade
RPS Group downgraded to Hold from Buy at Liberum » 05:32
08/09/22
08/09
05:32
08/09/22
05:32
RPSGF

RPS Group

$1.30 /

+ (+0.00%)

Liberum analyst Alex…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPSGF RPS Group
$1.30 /

+ (+0.00%)

06/27/22 Berenberg
RPS Group price target raised to 150 GBp from 145 GBp at Berenberg
03/17/22 RBC Capital
RPS Group price target raised to 135 GBp from 130 GBp at RBC Capital
Downgrade
Nike downgraded to Neutral from Outperform at Exane BNP Paribas » 05:30
08/09/22
08/09
05:30
08/09/22
05:30
NKE

Nike

$114.01 /

+0.13 (+0.11%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NKE Nike
$114.01 /

+0.13 (+0.11%)

NKE Nike
$114.01 /

+0.13 (+0.11%)

07/25/22 Piper Sandler
Nike assumed with a Neutral at Piper Sandler
07/21/22 KeyBanc
KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
07/20/22 KeyBanc
Nike initiated with a Sector Weight at KeyBanc
07/20/22 Stifel
Nike price target lowered to $130 from $135 at Stifel
NKE Nike
$114.01 /

+0.13 (+0.11%)

NKE Nike
$114.01 /

+0.13 (+0.11%)

NKE Nike
$114.01 /

+0.13 (+0.11%)

NKE Nike
$114.01 /

+0.13 (+0.11%)

Initiation
RMR Group assumed with a Perform at Oppenheimer » 05:29
08/09/22
08/09
05:29
08/09/22
05:29
RMR

RMR Group

$28.45 /

-0.065 (-0.23%)

Oppenheimer analyst Chris…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RMR RMR Group
$28.45 /

-0.065 (-0.23%)

RMR RMR Group
$28.45 /

-0.065 (-0.23%)

05/20/22 RBC Capital
RMR Group price target lowered to $32 from $36 at RBC Capital
05/13/22 B. Riley
RMR Group price target raised to $44 from $42 at B. Riley
01/31/22 B. Riley
RMR Group price target lowered to $42 from $44 at B. Riley
12/01/21 RBC Capital
RMR Group price target lowered to $35 from $42 at RBC Capital
RMR RMR Group
$28.45 /

-0.065 (-0.23%)

Initiation
Kindred Group initiated with an Underperform at BofA » 05:26
08/09/22
08/09
05:26
08/09/22
05:26
KNDGF

Kindred Group

$8.50 /

+ (+0.00%)

BofA initiated coverage…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KNDGF Kindred Group
$8.50 /

+ (+0.00%)

KNDGF Kindred Group
$8.50 /

+ (+0.00%)

07/28/22 Berenberg
Kindred Group price target lowered to SEK 113 from SEK 123 at Berenberg
04/29/22 Deutsche Bank
Kindred Group price target lowered to SEK 123 from SEK 127 at Deutsche Bank
01/31/22 Deutsche Bank
Kindred Group price target lowered to SEK 127 from SEK 133 at Deutsche Bank
01/07/22 Berenberg
Kindred Group initiated with a Buy at Berenberg

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.